Five toxicologic pathologists offer their perspectives on the benefits and challenges of forging a career in toxicology.
The devil is in the details when it comes to ensuring reliable, reproducible immunopotency assays in vaccine testing.
While the process of drug discovery remains constant, the groups driving the scientific innovation now include those typically associated with fund-raising, lobbying and patient advocacy. Along with biopharmaceutical companies, which have been at the helm of drug discovery for years, one finds an increasing number of not-for-profit disease foundations angling for a seat at the lab bench.
While challenges remain, PCR-based strategies for direct testing of quarantined rodents and for monitoring dust can replace, reduce or refine the use of sentinel mice in the infectious screening process, supporting the 3R philosophy while greatly improving the detection of rodent infectious agents to help keep animal colonies safe.
Live from the JP Morgan Healthcare Conference, James Foster, chairman and CEO at Charles River Laboratories spoke with Mad Money on CNBC. James Foster and Jim Cramer discuss the company’s strategic focus on helping accelerate drug discovery and development.
CHDI Foundation, Inc. has extended its ongoing collaboration with Charles River Laboratories for discovering novel drugs for Huntington's disease for an additional five years.
An approach to consider for detecting latent or endogenous viruses in cell substrates is the use of assays that employ specific chemical compounds to induce virus expression or replication. Following induction, latent and endogenous viruses can then be detected through subsequent assays, such as TEM and QF-PCR testing.
When targeting genes, drug developers may opt for knockdown via CRISPR or silencing via RNAi. These weapons, however, may fit different battle plans.
Don’t fall into the cell line misidentification trap. Authenticate! What you don’t know–or what you refuse to acknowledge–will hurt you.
Today, Charles River Laboratories announced that CHDI Foundation, Inc. has extended its ongoing collaboration for an additional five years. The collaboration, which began in 2005, is focused on discovering novel drugs for Huntington's disease. CHDI has expanded the collaboration with Charles River due to its neuroscience expertise and comprehensive integrated drug discovery capability.